HPV Related Disease Burden and Impact of HPV Vaccine

Overview

Human Papilloma Virus (HPV) infections are very common and can lead to several cancers. A safe and effective vaccine exists to prevent these cancers. The optimal age for administration of the HPV vaccine is before exposure to HPV. The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends administration to youth between 11-12 years of age. HPV vaccine is safe and effective in preventing disease. Even though we have an excellent preventive tool, the rates of HPV vaccination remain suboptimal.

Since this webinar aired there have been updates to the recommendations from the Center for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) for HPV vaccine and data related to HPV prevalence; vaccine safety, efficacy, and duration of protection; and HPV vaccine coverage estimates.

The updated ACIP recommendations were published in the Morbidity and Mortality Weekly Report on August 16, 2019. These updates included a harmonization of a catch-up recommendation for men and women through age 26 years. The recommendations also included a shared clinical decision-making recommendation for adults aged 27-45 years. The complete recommendation updates, including considerations for the shared clinical decision-making for 27-45-year-old adults.

Updated data can be found at the following CDC links:

• Prevalence of HPV in Adults Aged 18–69: United States, 2011–2014
• Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine — United States, 2003-2018
• HPV Vaccine Safety and Effectiveness
• Teen Vaccination Coverage Publications and Resources
• TeenVaxView Interactive

Target Audience 

Pediatricians and family physicians, as well as nurses, physician assistants, nurse practitioners, and other medical providers who see adolescents/pre-adolescents in their practice.